Can a pill help keep advanced lung cancer at bay?
NCT ID NCT07744698
First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time
Summary
This trial is testing whether a pill form of the chemotherapy drug paclitaxel, taken alongside an immune checkpoint inhibitor, can help people with advanced lung cancer stay stable longer after their first round of treatment. The study includes two groups: one with squamous non-small cell lung cancer and another with extensive-stage small cell lung cancer. Participants will take oral paclitaxel three times a week plus the same immunotherapy they received initially. The main goal is to see how long the cancer stays under control, with additional measures of tumor response, overall survival, side effects, and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- oral paclitaxel combined with a PD-1 or PD-L1 inhibitor
- What this could lead to
- If successful, this could offer a more convenient maintenance option to help keep advanced lung cancer from progressing after initial treatment.
- What could go wrong
- This is an exploratory study, so results may not be conclusive. Side effects from the combination could be significant, and the benefit over standard care is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Anhui Cancer Hospital
RECRUITINGHefei, Anhui, 230031, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Cholesterol-Lowering drug may boost lung cancer immunotherapy
- New vaccine combo takes on tough lung cancer in early trial
- Engineered immune cells take on tough lung cancer
- New hope for advanced lung cancer: chemo-radiation combo enters trial
- New drug duo aims to shrink tough lung cancer in 33-patient trial
- New hope for aggressive lung cancer: experimental drug combo enters final testing